The Effect of Intravenous Lidocaine on EC50 of Remifentanil for Preventing Cough During Emergence in Female for Thyroid Surgery Anesthesia.

IF 4.7 2区医学 Q1 CHEMISTRY, MEDICINAL

Drug Design, Development and Therapy Pub Date : 2024-12-20 eCollection Date: 2024-01-01 DOI:10.2147/DDDT.S496608

Zheng-Lun Lin, Li Liu, Kai Shi, Tian-Jie Chen, Lin-Ming Chen, Hong-da Cai

{"title":"The Effect of Intravenous Lidocaine on EC50 of Remifentanil for Preventing Cough During Emergence in Female for Thyroid Surgery Anesthesia.","authors":"Zheng-Lun Lin, Li Liu, Kai Shi, Tian-Jie Chen, Lin-Ming Chen, Hong-da Cai","doi":"10.2147/DDDT.S496608","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the effect of intravenous lidocaine injection on the half-maximum effective concentration (EC50) of remifentanil in preventing cough due to tracheal extubation in female patients undergoing thyroid surgery by Dixon's sequential method.Methods: A total of 50 female patients underwent elective thyroidectomy were randomly divided into two groups of a 1:1 ratio. Group L (lidocaine group) was given intravenous lidocaine (1.5 mg/kg) and then continuous infusion (2 mg/kg/h) until the end of surgery. Group C (control group) received 0.9% sodium chloride solution infusion in the same way. The primary outcome was effective concentration EC50 of remifentanil in preventing cough due to tracheal extubation in female patients undergoing thyroid surgery. The secondary outcomes were as follows: mean arterial pressure (MAP), oxygen saturation (SpO2), heart rate (HR), PetCO2 and respiratory rate at the time of tracheal extubation. The incidence of postoperative nausea and vomiting, and symptoms associated with lidocaine toxicity.Results: Finally, 44 subjects completed the study. The EC50 values of remifentanil calculated using probit regression were 1.40 ng/mL (95% CI, 1.15-1.65 ng/mL) in Group C and 0.83 ng/mL (95% CI, 0.58-1.08 ng/mL) in Group L. A lower concentration of remifentanil can inhibit the cough reaction during intravenous lidocaine infusion. PetCO2 in the lidocaine group was lower than that in the control group (Z=-2.162, P < 0.05). The respiratory rate of the lidocaine group after extubation was higher than that of the control group (Z=-3.287, P < 0.05).Conclusion: Intravenous injection of lidocaine can reduce the effective concentration EC50 of remifentanil in preventing tracheal extubation cough in female patients undergoing thyroid surgery.","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"6165-6172"},"PeriodicalIF":4.7000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668315/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S496608","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the effect of intravenous lidocaine injection on the half-maximum effective concentration (EC50) of remifentanil in preventing cough due to tracheal extubation in female patients undergoing thyroid surgery by Dixon's sequential method.

Methods: A total of 50 female patients underwent elective thyroidectomy were randomly divided into two groups of a 1:1 ratio. Group L (lidocaine group) was given intravenous lidocaine (1.5 mg/kg) and then continuous infusion (2 mg/kg/h) until the end of surgery. Group C (control group) received 0.9% sodium chloride solution infusion in the same way. The primary outcome was effective concentration EC50 of remifentanil in preventing cough due to tracheal extubation in female patients undergoing thyroid surgery. The secondary outcomes were as follows: mean arterial pressure (MAP), oxygen saturation (SpO₂), heart rate (HR), PetCO₂ and respiratory rate at the time of tracheal extubation. The incidence of postoperative nausea and vomiting, and symptoms associated with lidocaine toxicity.

Results: Finally, 44 subjects completed the study. The EC50 values of remifentanil calculated using probit regression were 1.40 ng/mL (95% CI, 1.15-1.65 ng/mL) in Group C and 0.83 ng/mL (95% CI, 0.58-1.08 ng/mL) in Group L. A lower concentration of remifentanil can inhibit the cough reaction during intravenous lidocaine infusion. PetCO₂ in the lidocaine group was lower than that in the control group (Z=-2.162, P < 0.05). The respiratory rate of the lidocaine group after extubation was higher than that of the control group (Z=-3.287, P < 0.05).

Conclusion: Intravenous injection of lidocaine can reduce the effective concentration EC50 of remifentanil in preventing tracheal extubation cough in female patients undergoing thyroid surgery.

查看原文本刊更多论文

静脉注射利多卡因对瑞芬太尼预防女性甲状腺手术麻醉急诊咳嗽EC50的影响。

目的通过迪克森序列法评估静脉注射利多卡因对瑞芬太尼半数最大有效浓度（EC50）的影响，以预防女性甲状腺手术患者因气管拔管引起的咳嗽：将 50 名接受甲状腺择期切除术的女性患者按 1:1 的比例随机分为两组。L组（利多卡因组）静脉注射利多卡因（1.5 mg/kg），然后持续输注（2 mg/kg/h）直至手术结束。C组（对照组）以同样的方式输注0.9%氯化钠溶液。主要结果是瑞芬太尼在预防女性甲状腺手术患者因气管插管引起的咳嗽方面的有效浓度EC50。次要结果如下：气管拔管时的平均动脉压（MAP）、血氧饱和度（SpO2）、心率（HR）、PetCO2和呼吸频率。术后恶心和呕吐的发生率以及与利多卡因毒性相关的症状：最后，44 名受试者完成了研究。使用 probit 回归法计算的瑞芬太尼 EC50 值为：C 组 1.40 纳克/毫升（95% CI，1.15-1.65 纳克/毫升），L 组 0.83 纳克/毫升（95% CI，0.58-1.08 纳克/毫升）。利多卡因组的 PetCO2 低于对照组（Z=-2.162，P＜0.05）。利多卡因组拔管后的呼吸频率高于对照组（Z=-3.287，P＜0.05）：结论：静脉注射利多卡因可降低瑞芬太尼的有效浓度EC50，预防女性甲状腺手术患者气管拔管咳嗽。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.